PT-141 before & after.

PT-141 before and after: what actually improved?

About 58% of women receiving bremelanotide reported a benefit in the two pivotal trials, compared with 35–36% receiving placebo. The measured changes were greater sexual desire and less distress about low desire. An increase in the number of satisfying sexual events was not demonstrated in those trials. [1]

FDA-label results from two studies of 1.75 mg subcutaneous bremelanotide used as needed. Last assessment within a 24-week treatment period; questionnaires use different scales. [2]

For someone starting with very little interest, a useful change could be wanting sex more often or feeling less troubled by its absence. The trial averages show the size of that change across groups; they do not identify a predictable response after each individual administration.

Sexual desire: starting score and change

The average desire score started near 2 and increased to approximately 2.6 in the treated groups. The questionnaire combines how often sexual interest occurs with its reported strength. Its range is 1.2–6, with higher values reflecting greater desire. [2]

*After-values are arithmetic reconstructions from the FDA label’s rounded baseline means plus rounded mean changes. They are not separately reported endpoint means. “After” means the last available assessment during the 24-week study, including earlier final visits. [2]

A half-point change can be worthwhile to an individual, but it is not the same as moving from no interest to consistently high desire. The group average combines larger improvements, small changes and nonresponse.

Dividing these scores to produce a “25% libido boost” would be misleading. The questionnaire is a rating scale, not a measurement of a physical quantity with a true zero. Reported response percentages describe people meeting a stated improvement criterion, not a percentage increase in the intensity of desire.

Distress: how bothered women felt

Average distress fell from 2.9 to approximately 2.2 in each bremelanotide group. This question asks how often the participant is bothered by low desire. The scale runs from zero to four, so a lower result reflects less bother. [2]

*Calculated from rounded means as above. A decrease is an improvement for this distress measure. [2]

Less distress is a distinct outcome even when sexual frequency does not change. A participant could feel more comfortable with her sexual interest or less troubled by the problem. These scores cannot diagnose or measure a treatment effect on a separate anxiety disorder, and they do not establish that relationship difficulties have resolved.

What does the 58% response figure mean?

The perceived-benefit response was 58.3% in Study 1 and 58.2% in Study 2. Placebo responses were 36.1% and 35.4%. The classification came from a patient assessment of benefit while taking study treatment. [1]

The differences are 22.2 and 22.8 percentage points. Expressed as a simple illustration, approximately 22–23 additional women per 100 met the response definition in the treated groups compared with placebo. This arithmetic does not identify which individual will benefit or establish an equivalent result from a research vial.

There is also room between “some benefit” and a dramatic transformation. A responder can improve without having high desire every day. A response percentage should therefore be paired with the actual average score changes, rather than used as a promise that treatment will solve every part of someone’s sexual experience.

First use, four weeks and eight weeks

The approved injection is taken at least 45 minutes before anticipated activity; overall improvement was measured from week four onward. These timings describe different things. One concerns planning an individual administration. The other concerns the earliest scheduled questionnaire assessment in the pivotal trials. [2] [1]

The four-week result does not mean a daily build-up period is required. Participants used treatment around anticipated activity, and most used the approved product two or three times per month in the pivotal program. The current label permits no more than one administration within 24 hours and recommends no more than eight monthly doses. [2]

Feeling nothing at exactly 45 minutes is not evidence that another immediate dose is needed. Timing and response vary, and the label does not establish benefit from repeating a dose within the same day. The dosage page gives the complete timing and quantity context.

How long do the effects last?

A precise 12-, 24- or 72-hour benefit window has not been established. The current prescribing information explicitly leaves the duration of efficacy after each dose undefined. The approximately 2.7-hour elimination half-life describes drug levels falling in the body; it does not measure how long increased desire lasts. [2]

Similarly, an early experiment observing participants for six hours is not proof of six hours of continuous benefit. A questionnaire completed the following day does not mean everyone experiences a full day of increased arousal. A useful individual change may be brief, variable or absent, even though a group average favours treatment.

Prolonged discomfort, an unwanted persistent erection or intense nausea should not be counted as a better response. The meaningful outcome is a wanted improvement that remains comfortable and tolerable.

Did women have more satisfying sexual encounters?

The pivotal trials did not demonstrate a significant increase in the number of satisfying sexual events. In the combined analysis, the average change was approximately zero with bremelanotide and −0.1 with placebo on the study’s event-count outcome. Desire and distress nevertheless improved. [1]

An earlier 12-week study gave a more positive event-count result: the pooled 1.25 mg and 1.75 mg groups increased by 0.7 satisfying encounters per month, versus 0.2 with placebo. That difference was about half an additional event per month. The study included 327 participants in its efficacy analysis and a mixture of low-desire and arousal diagnoses. [3]

The earlier and later outcomes should both remain visible. The smaller study cannot support a fixed promise of additional satisfying encounters when the larger pivotal trials did not confirm that benefit. More desire, more frequent sex and greater satisfaction are related but separately measured outcomes.

Before-and-after results in men

Early male research measured increased erectile activity, rather than a dependable percentage of successful home encounters. A 2004 subcutaneous study found significant responses with supervised 4 mg and 6 mg amounts in men who reported an inadequate Viagra response, while they received visual sexual stimulation. Those experimental amounts are not an approved male regimen. [4]

Another small study tested intranasal PT-141, with the first erection appearing at approximately 30 minutes and significant responses at amounts above 7 mg. A separate 19-man crossover study found a stronger monitored response when 7.5 mg intranasal PT-141 was added to 25 mg sildenafil than with sildenafil alone. [5] [6]

A monitoring device can establish a physical response under study conditions. It cannot establish that the supplied nasal bottle will produce a particular duration, that an erection will occur without stimulation, or that a man’s lack of desire will resolve.

The widely repeated 33.5% success figure from a 2008 sildenafil-failure study is especially unsuitable as a consumer expectation: that paper received an expression of concern in 2023. The journal’s concern prevents treating that percentage as a dependable male success rate. [7]

Nasal results: one small women’s study

A 2006 crossover study tested a single 20 mg nasal administration in 18 women with arousal disorder. More women reported moderate or high desire after bremelanotide than after placebo. Among those who attempted intercourse in the following 24 hours, satisfaction with arousal improved. The laboratory measure of vaginal blood-flow response did not significantly differ. [8]

That is a small, formulation-specific finding. It supplies neither a reliable success percentage for routine nasal use nor a number of sprays for another product. The supplied spray has conflicting strength and formulation information, detailed in the product comparison.

A separate 2008 women’s study was retracted. Its claimed improvements should not be added to this evidence or used to make the nasal results appear stronger. [9]

Results with longer treatment

Some women maintained improved desire during an additional 52-week extension. After the 24-week controlled trials, 684 participants chose to continue and 272 completed the extension. Everyone received bremelanotide during that period, so there was no continuing placebo comparison. [10]

For women who had received bremelanotide from the core phase onward, the reported changes from the original baseline were about +1.25 to +1.30 points for desire and −1.4 to −1.7 for related distress at the extension endpoint. These larger changes came from a selected continuing population. They cannot be substituted for the average result among everyone originally randomized.

Only about 40% of the extension entrants completed it. Continuing participants had already reached the end of the initial study and chosen more treatment; adverse events and withdrawal of consent were common reasons for later stopping. The extension supports the possibility of sustained benefit in some users, without establishing that most people will improve progressively for a year.

What happens after stopping?

The trials do not establish a permanent increase in libido after treatment ends. They primarily assessed experience during as-needed treatment. There is no supported number of days before desire returns to a previous level, and no established “reset” course that guarantees a lasting change.

For the approved prescription, eight weeks without improvement is a reason to stop and revisit the treatment plan. Persistent symptoms may warrant reassessing their cause rather than increasing the amount or adding a nasal product. The benefits article separates desire, physical arousal and erection quality; the side-effects article covers symptoms that can outweigh a benefit. [2]